
Novo Nordisk’s CEO Departure Marks Inflection Point for Struggling Pharma Giant
Novo Nordisk A/S (NYSE:NVO) announced that CEO Lars Fruergaard Jørgensen is stepping down amid mounting challenges, with the company’s share price down more than 50% since mid-2024 as competition intensifies in the obesity drug market and disappointing …